Appendix 3B

New issue announcement,

application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity	
Anteo Diagnostics Limited	
ABN	
75 070 028 625	

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	⁺ Class of ⁺ securities issued or to be issued	Unlisted Options
2	Number of +securities issued or to be	32,200,000 Unlisted Options
	issued (if known) or maximum number	62,200,000 Cimist cu Spusins
	which may be issued	(2,000,000) Unlisted Options - lapsed
	•	(2,000,000) Offisied Options - Tapsed
3	Principal terms of the +securities (eg, if	22 200 000 00 020 11 1 1
_	options, exercise price and expiry date; if	32,200,000 \$0.030 unlisted options expiry
	partly paid +securities, the amount	5 October 2018
	outstanding and due dates for payment; if	
	+convertible securities, the conversion	
	price and dates for conversion)	
	r	

⁺ See chapter 19 for defined terms.

4	Do the ⁺ securities rank equally in all respects from the date of allotment with an existing ⁺ class of quoted ⁺ securities?	N/A
	If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To issue 32,200,000 \$0.030 unlisted options expiry 5/10/2018 pursuant to the Shareholder Loan Agreements. Expiry of 2,000,000 Unlisted Options at \$0.06 exercise prices and expiry 1/08/2020.
ба	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the ⁺securities the subject of this Appendix 3B</i> , and comply with section 6i	No
CI.		
6b	The date the security holder resolution under rule 7.1A was passed	
6c	Number of *securities issued without security holder approval under rule 7.1	
6d	Number of *securities issued with security holder approval under rule 7.1A	
бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	
6f	Number of securities issued under an	
	exception in rule 7.2	

6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.		
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer Annexure 1	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	6/04/2017	
		Number	+Class
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in section 2 if applicable)	1,133,929,581	Fully Paid Ordinary Shares
9	Number and *class of all *securities not quoted on ASX (<i>including</i> the securities in section 2 if applicable)	32,200,000 2,000,000 17,200,000 1,400,000 13,000,000 1,000,000 67,500,000	3.0c Unlisted options 7.8c Unlisted options 12.0c Unlisted options 13.5c Unlisted options 20.0c Unlisted options 25.0c Unlisted options
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)		
Part	2 - Bonus issue or pro rata is	sue	
11	Is security holder approval required?		
12	Is the issue renounceable or non-renounceable?		
13	Ratio in which the *securities will be offered		

⁺ See chapter 19 for defined terms.

	-	
14	⁺ Class of ⁺ securities to which the offer relates	
	offer ferates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents Note: Security holders must be told how their	
	entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders*	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	

27	the te	entity has issued options, and erms entitle option holders to sipate on exercise, the date on a notices will be sent to option ers	
28		rights trading will begin (if cable)	
29		rights trading will end (if cable)	
30		do ⁺ security holders sell their ements <i>in full</i> through a er?	
31	of th	do ⁺ security holders sell <i>part</i> neir entitlements through a er and accept for the balance?	
32	their	do *security holders dispose of entitlements (except by sale gh a broker)?	
33	⁺ Desp	patch date	
		Quotation of securitie	
34	Type (tick o	of securities one)	
(a)			
(b)		All other securities	
			of the escrowed period, partly paid securities that become fully paid, employee ands, securities issued on expiry or conversion of convertible securities
Entiti	es tha	t have ticked box 34(a)	
Addit	ional s	securities forming a new cla	ass of securities
Tick to docume		te you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the number and percentage of additional *securities held by

+ See chapter 19 for defined terms.

36	If the +securities are +equity s +securities setting out the number 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	securities, a distribution schedule of the additional of holders in the categories
37	A copy of any trust deed for the a	additional ⁺ securities
Entiti	ies that have ticked box 34(b)	
38	Number of securities for which ⁺ quotation is sought	
39	Class of *securities for which quotation is sought	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)	
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)	

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 +securities to be quoted under section 1019B of the Corporations Act at the
 time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Peter Harding-Smith Date:13 April 2017

(Company secretary)

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	1,050,188,402	
 Add the following: Number of fully paid ordinary securities issued in that 12 month period under an 	77,963,722 Bergen shares ratified at 2016 AGM	
exception in rule 7.2	5,777,457 Bergen shares ratified at 2016 AGM	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval		
 Number of partly paid ordinary securities that became fully paid in that 12 month period 		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	nil	
"A"	1,133,929,581	

C4am 2: Calaulata 450/ a5 "A"		
Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	170,089,437	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
Under an exception in rule 7.2		
Under rule 7.1A		
With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	nil	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	170,089,437	
Note: number must be same as shown in Step 2		
Subtract "C"	Nil	
Note: number must be same as shown in Step 3		
Total ["A" x 0.15] – "C"	170,089,437	

⁺ See chapter 19 for defined terms.

Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A"	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	
Insert number of equity securities issued or agreed to be issued in that 12 month period	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10		
Note: number must be same as shown in Step 2		
Subtract "E"	nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"		

⁺ See chapter 19 for defined terms.